University of Washington-Seattle Campus · BiologyAntiviral Drug Development Unit
Stephen J. Polyak · Seattle, Washington
Research Focus
Dr. Stephen J. Polyak's lab at the University of Washington focuses on developing new antiviral treatments specifically for coronaviruses. The research aims to create a combination of oral medications that can effectively treat patients infected with SARS-CoV-2 and other related viruses. By utilizing advanced mathematical models, the lab seeks to optimize drug combinations and dosing strategies, improving global preparedness for future outbreaks.
coronavirusantiviral drugsdrug combinationsSARS-CoV-2COVID-19pandemic preparednessmathematical modeling
Research Aims
5AIM 01Develop a pan-coronavirus drug cocktail that can be used against multiple strains.
AIM 02Utilize mathematical modeling to optimize drug combinations and dosing strategies.
AIM 03Test synergistic drug combinations in rodent models of infection.
AIM 04Provide efficient clinical trial designs for new antiviral treatments.
AIM 05Enhance global response preparedness against future coronavirus outbreaks.
Skills the Lab Values
mathematical modelinganimal modelsdrug interaction testingcell cultureclinical trial designvirus infection assayspharmacokineticsdata analysis softwarein vitro testing
Output against the department
Publications166top 40% of dept.414th of 1,033
this lab
most publishedleast published
Citations9.9ktop 38% of dept.393rd of 1,033
this lab
most citedleast cited
Career totals from OpenAlex, compared against labs that share a department. A department spans everything from one paper to tens of thousands, so bar heights are on a log scale — otherwise the largest lab would flatten every other bar to a line.